{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:20:41Z","timestamp":1793330441157,"version":"4.5.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T00:00:00Z","timestamp":1695081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T00:00:00Z","timestamp":1695081600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Council for Development of Stem Cell Sciences and Technologies"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Allo-HSCT is a definite approach for the management of a wide variety of lethal and debilitating malignant and non-malignant disorders. However, its two main complications, acute and chronic graft-versus-host disease (GVHD), exert significant morbidities and mortalities. BoS, as a manifestation of chronic lung GVHD, is a gruesome complication of allo-HSCT, and for those with steroid-refractory disease, no approved second-line therapies exist. Mesenchymal stem cells (MSCs) exert anti-inflammatory and growth-promoting effects, and their administration against a wide range of inflammatory and neurologic disorders, as well as GVHD, has been associated with promising outcomes. However, literature on the safety and effectiveness of MSC therapy for BoS and pediatric cGVHD is scarce.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We designed a single-arm trial to administer adipose tissue (AT)-derived MSCs to pediatric patients with refractory BoS after allo-HSCT. AT-MSCs from obese, otherwise healthy donors were cultured in an ISO class 1 clean room and injected into the antecubital vein of eligible patients with a dose of 1\u2009\u00d7\u200910<jats:sup>6<\/jats:sup>\/kg. The primary endpoints included a complete or partial response to therapy [in terms of increased forced expiratory volume in one second (FEV1) values and steroid dose reduction] and its safety profile.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Four eligible patients with a median age of 6.5 years were enrolled in the study. Steroid-induced osteoporosis and myopathy were present in three cases. A partial response was evident in three cases after a single injection of AT-MSCs. The treatment was safe and tolerable, and no treatment-related adverse events were noted. Two patients developed manageable COVID-19 infections one and 4 months after AT-MSC injection. After a median follow-up duration of 19 months, all cases are still alive and have had no indications for lung transplantation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>AT-MSCs could be safely administered to our pediatric cases with BoS post-allo-HSCT. Considering their advanced stage of disease, their sub-optimal functional capacity due to steroid-induced complications, and COVID-19 infection post-treatment, we believe that AT-MSC therapy can have possible efficacy in the management of pediatric BoS. The conduction of further studies with larger sample sizes and more frequent injections is prudent for further optimization of AT-MSC therapy against BoS.<\/jats:p>\n                <jats:p><jats:italic>Trial registration<\/jats:italic> Iranian Registry of Clinical Trials (IRCT), IRCT20201202049568N2. Registered 22 February 2021, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/en.irct.ir\/trial\/53143\">https:\/\/en.irct.ir\/trial\/53143<\/jats:ext-link>.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13287-023-03498-y","type":"journal-article","created":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T19:01:54Z","timestamp":1695150114000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Evaluation of safety and efficacy of allogeneic adipose tissue-derived mesenchymal stem cells in pediatric bronchiolitis obliterans syndrome (BoS) after allogeneic hematopoietic stem cell transplantation (allo-HSCT)"],"prefix":"10.1186","volume":"14","clinical-trial-number":[{"clinical-trial-number":"irct20201202049568n2","registry":"10.18810\/irct"}],"author":[{"given":"Rashin","family":"Mohseni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pouya","family":"Mahdavi Sharif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Behfar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Reza","family":"Modaresi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohola","family":"Shirzadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahta","family":"Mardani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Jafari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahimeh","family":"Jafari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeynab","family":"Nikfetrat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8935-079X","authenticated-orcid":false,"given":"Amir Ali","family":"Hamidieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,19]]},"reference":[{"issue":"17","key":"3498_CR1","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMra052638","volume":"354","author":"EA Copelan","year":"2006","unstructured":"Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006;354(17):1813\u201326.","journal-title":"N Engl J Med"},{"issue":"1","key":"3498_CR2","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1182\/hematology.2021000266","volume":"2021","author":"L Luzzatto","year":"2021","unstructured":"Luzzatto L. Diagnosis and clinical management of enzymopathies. Hematol Am Soc Hematol Educ Progr. 2021;2021(1):341\u201352.","journal-title":"Hematol Am Soc Hematol Educ Progr"},{"issue":"5","key":"3498_CR3","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.3324\/haematol.2021.279189","volume":"107","author":"D Niederwieser","year":"2022","unstructured":"Niederwieser D, Baldomero H, Bazuaye N, Bupp C, Chaudhri N, Corbacioglu S, et al. One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors. Haematologica. 2022;107(5):1045\u201353.","journal-title":"Haematologica"},{"issue":"22","key":"3498_CR4","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1056\/NEJMra1609337","volume":"377","author":"R Zeiser","year":"2017","unstructured":"Zeiser R, Blazar BR. Acute graft-versus-host disease: biologic process, prevention, and therapy. N Engl J Med. 2017;377(22):2167\u201379.","journal-title":"N Engl J Med"},{"issue":"5","key":"3498_CR5","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41409-018-0333-z","volume":"54","author":"MS Saleem","year":"2019","unstructured":"Saleem MS, Aljurf M, Srivastava A, Shamsi T, Lu PH, Hamidieh AA, et al. Challenges in managing graft-versus-host disease in developing countries: a perspective. Bone Marrow Transpl. 2019;54(5):641\u20137.","journal-title":"Bone Marrow Transpl"},{"issue":"26","key":"3498_CR6","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1056\/NEJMra1703472","volume":"377","author":"R Zeiser","year":"2017","unstructured":"Zeiser R, Blazar BR. Pathophysiology of chronic graft-versus-host disease and therapeutic targets. N Engl J Med. 2017;377(26):2565\u201379.","journal-title":"N Engl J Med"},{"issue":"1","key":"3498_CR7","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.pcl.2009.11.003","volume":"57","author":"K Baird","year":"2010","unstructured":"Baird K, Cooke K, Schultz KR. Chronic graft-versus-host disease (GVHD) in children. Pediatr Clin North Am. 2010;57(1):297\u2013322.","journal-title":"Pediatr Clin North Am"},{"issue":"1","key":"3498_CR8","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s41409-019-0651-9","volume":"55","author":"ML MacMillan","year":"2020","unstructured":"MacMillan ML, Holtan SG, Rashidi A, DeFor TE, Blazar BR, Weisdorf DJ. Pediatric acute GVHD: clinical phenotype and response to upfront steroids. Bone Marrow Transpl. 2020;55(1):165\u201371.","journal-title":"Bone Marrow Transpl"},{"issue":"20","key":"3498_CR9","doi-asserted-by":"publisher","first-page":"4278","DOI":"10.1182\/bloodadvances.2021004941","volume":"5","author":"Z DeFilipp","year":"2021","unstructured":"DeFilipp Z, Alousi AM, Pidala JA, Carpenter PA, Onstad LE, Arai S, et al. Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium. Blood Adv. 2021;5(20):4278\u201384.","journal-title":"Blood Adv"},{"key":"3498_CR10","doi-asserted-by":"crossref","unstructured":"Lueck C, Tzalavras A, Wohlfarth P, Meedt E, Kiehl M, Turki AT, et al. Impact of chronic graft-versus-host-disease on intensive care outcome in allogeneic hematopoietic stem cell recipients. Bone Marrow Transplant. 2022.","DOI":"10.1038\/s41409-022-01875-4"},{"key":"3498_CR11","doi-asserted-by":"crossref","unstructured":"Michonneau D, Quignot N, Jiang H, Reichenbach D, Kelly M, Burrell A, et al. Clinical and economic burden associated with graft-versus-host disease following allogeneic hematopoietic cell transplantation in France. Bone Marrow Transpl. 2023.","DOI":"10.1038\/s41409-023-01930-8"},{"key":"3498_CR12","doi-asserted-by":"crossref","unstructured":"Bergeron A, Chevret S, Peffault de Latour R, Chagnon K, de Margerie-Mellon C, Rivi\u00e8re F, et al. Noninfectious lung complications after allogeneic haematopoietic stem cell transplantation. Eur Respir J. 2018; 51(5).","DOI":"10.1183\/13993003.02617-2017"},{"issue":"6","key":"3498_CR13","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1038\/bmt.2014.25","volume":"49","author":"AG Vieira","year":"2014","unstructured":"Vieira AG, Funke VA, Nunes EC, Frare R, Pasquini R. Bronchiolitis obliterans in patients undergoing allogeneic hematopoietic SCT. Bone Marrow Transpl. 2014;49(6):812\u20137.","journal-title":"Bone Marrow Transpl"},{"issue":"7","key":"3498_CR14","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/j.bbmt.2010.11.018","volume":"17","author":"BK Au","year":"2011","unstructured":"Au BK, Au MA, Chien JW. Bronchiolitis obliterans syndrome epidemiology after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transpl. 2011;17(7):1072\u20138.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"19","key":"3498_CR15","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1056\/NEJMra1204664","volume":"370","author":"AF Barker","year":"2014","unstructured":"Barker AF, Bergeron A, Rom WN, Hertz MI. Obliterative bronchiolitis. N Engl J Med. 2014;370(19):1820\u20138.","journal-title":"N Engl J Med"},{"key":"3498_CR16","doi-asserted-by":"crossref","unstructured":"Soleimani M, Sharif PM, Cheraqpour K, Koganti R, Masoumi A, Baharnoori SM, et al. Ocular graft-versus-host disease (oGVHD): From A to Z. Surv Ophthalmol. 2023.","DOI":"10.1016\/j.survophthal.2023.02.006"},{"issue":"3","key":"3498_CR17","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","volume":"21","author":"MH Jagasia","year":"2015","unstructured":"Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I: the 2014 diagnosis and staging working group report. Biol Blood Marrow Transpl. 2015;21(3):389-401.e1.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"12","key":"3498_CR18","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","volume":"11","author":"AH Filipovich","year":"2005","unstructured":"Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I: diagnosis and staging working group report. Biol Blood Marrow Transpl. 2005;11(12):945\u201356.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"5","key":"3498_CR19","doi-asserted-by":"publisher","first-page":"264.e1","DOI":"10.1016\/j.jtct.2022.01.021","volume":"28","author":"KM Williams","year":"2022","unstructured":"Williams KM, Pavletic SZ, Lee SJ, Martin PJ, Farthing DE, Hakim FT, et al. Prospective phase II trial of montelukast to treat bronchiolitis obliterans syndrome after hematopoietic cell transplantation and investigation into bronchiolitis obliterans syndrome pathogenesis. Transpl Cell Ther. 2022;28(5):264.e1-e9.","journal-title":"Transpl Cell Ther"},{"issue":"4","key":"3498_CR20","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.bbmt.2015.10.009","volume":"22","author":"KM Williams","year":"2016","unstructured":"Williams KM, Cheng GS, Pusic I, Jagasia M, Burns L, Ho VT, et al. Fluticasone, azithromycin, and montelukast treatment for new-onset bronchiolitis obliterans syndrome after hematopoietic cell transplantation. Biol Blood Marrow Transpl. 2016;22(4):710\u20136.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"10","key":"3498_CR21","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1038\/bmt.2010.311","volume":"46","author":"BC Norman","year":"2011","unstructured":"Norman BC, Jacobsohn DA, Williams KM, Au BK, Au MA, Lee SJ, et al. Fluticasone, azithromycin and montelukast therapy in reducing corticosteroid exposure in bronchiolitis obliterans syndrome after allogeneic hematopoietic SCT: a case series of eight patients. Bone Marrow Transpl. 2011;46(10):1369\u201373.","journal-title":"Bone Marrow Transpl"},{"issue":"4","key":"3498_CR22","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1182\/blood-2016-08-693507","volume":"129","author":"KM Williams","year":"2017","unstructured":"Williams KM. How I treat bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation. Blood. 2017;129(4):448\u201355.","journal-title":"Blood"},{"issue":"3","key":"3498_CR23","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/s41409-018-0266-6","volume":"54","author":"A Hakim","year":"2019","unstructured":"Hakim A, Cooke KR, Pavletic SZ, Khalid M, Williams KM, Hashmi SK. Diagnosis and treatment of bronchiolitis obliterans syndrome accessible universally. Bone Marrow Transpl. 2019;54(3):383\u201392.","journal-title":"Bone Marrow Transpl"},{"issue":"7","key":"3498_CR24","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.bbmt.2011.11.031","volume":"18","author":"GA Yanik","year":"2012","unstructured":"Yanik GA, Mineishi S, Levine JE, Kitko CL, White ES, Vander Lugt MT, et al. Soluble tumor necrosis factor receptor: enbrel (etanercept) for subacute pulmonary dysfunction following allogeneic stem cell transplantation. Biol Blood Marrow Transpl. 2012;18(7):1044\u201354.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"7","key":"3498_CR25","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1038\/s41409-019-0450-3","volume":"54","author":"M Schoettler","year":"2019","unstructured":"Schoettler M, Duncan C, Lehmann L, Furutani E, Subramaniam M, Margossian S. Ruxolitinib is an effective steroid sparing agent in children with steroid refractory\/dependent bronchiolitis obliterans syndrome after allogenic hematopoietic cell transplantation. Bone Marrow Transpl. 2019;54(7):1158\u201360.","journal-title":"Bone Marrow Transpl"},{"issue":"4","key":"3498_CR26","doi-asserted-by":"publisher","first-page":"e28190","DOI":"10.1002\/pbc.28190","volume":"67","author":"V Uygun","year":"2020","unstructured":"Uygun V, Karasu G, Dalo\u011flu H, \u00d6zt\u00fcrkmen S, K\u0131l\u0131\u00e7 S, Yal\u00e7\u0131n K, et al. Ruxolitinib salvage therapy is effective for steroid-refractory graft-versus-host disease in children: a single-center experience. Pediatr Blood Cancer. 2020;67(4):e28190.","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"3498_CR27","first-page":"S279","volume":"29","author":"AA Hamidieh","year":"2023","unstructured":"Hamidieh AA, Jafari L, Delkhah M, Asefi N, Karamlou Y, Mohseni R, et al. The outcome of extracorporeal photopheresis using cryopreservation in pediatric patients with acute and chronic gvhd at the largest children\u2019s medical hospital in Iran. Transpl Cell Therapy Offic Pub Am Soc Transpl Cell Therapy. 2023;29(2):S279\u201380.","journal-title":"Transpl Cell Therapy Offic Pub Am Soc Transpl Cell Therapy"},{"issue":"2","key":"3498_CR28","doi-asserted-by":"publisher","first-page":"100","DOI":"10.5045\/br.2014.49.2.100","volume":"49","author":"MI Malik","year":"2014","unstructured":"Malik MI, Litzow M, Hogan W, Patnaik M, Murad MH, Prokop LJ, et al. Extracorporeal photopheresis for chronic graft-versus-host disease: a systematic review and meta-analysis. Blood Res. 2014;49(2):100\u20136.","journal-title":"Blood Res"},{"issue":"4","key":"3498_CR29","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1097\/00007890-197404000-00001","volume":"17","author":"AJ Friedenstein","year":"1974","unstructured":"Friedenstein AJ, Chailakhyan RK, Latsinik NV, Panasyuk AF, Keiliss-Borok IV. Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues: cloning in vitro and retransplantation in vivo. Transplantation. 1974;17(4):331\u201340.","journal-title":"Transplantation"},{"issue":"2","key":"3498_CR30","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1089\/107632701300062859","volume":"7","author":"PA Zuk","year":"2001","unstructured":"Zuk PA, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ, et al. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng. 2001;7(2):211\u201328.","journal-title":"Tissue Eng"},{"issue":"8","key":"3498_CR31","first-page":"1017","volume":"91","author":"LL Lu","year":"2006","unstructured":"Lu LL, Liu YJ, Yang SG, Zhao QJ, Wang X, Gong W, et al. Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials. Haematologica. 2006;91(8):1017\u201326.","journal-title":"Haematologica"},{"issue":"1","key":"3498_CR32","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1038\/s41598-023-28478-3","volume":"13","author":"P Wuttisarnwattana","year":"2023","unstructured":"Wuttisarnwattana P, Eid S, Wilson DL, Cooke KR. Assessment of therapeutic role of mesenchymal stromal cells in mouse models of graft-versus-host disease using cryo-imaging. Sci Rep. 2023;13(1):1698.","journal-title":"Sci Rep"},{"issue":"9","key":"3498_CR33","doi-asserted-by":"publisher","first-page":"3722","DOI":"10.1182\/blood-2002-07-2104","volume":"101","author":"M Krampera","year":"2003","unstructured":"Krampera M, Glennie S, Dyson J, Scott D, Laylor R, Simpson E, et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood. 2003;101(9):3722\u20139.","journal-title":"Blood"},{"key":"3498_CR34","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3389\/fimmu.2013.00201","volume":"4","author":"AM Dimarino","year":"2013","unstructured":"Dimarino AM, Caplan AI, Bonfield TL. Mesenchymal stem cells in tissue repair. Front Immunol. 2013;4:201.","journal-title":"Front Immunol"},{"issue":"1","key":"3498_CR35","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1186\/s13287-022-03054-0","volume":"13","author":"R Margiana","year":"2022","unstructured":"Margiana R, Markov A, Zekiy AO, Hamza MU, Al-Dabbagh KA, Al-Zubaidi SH, et al. Clinical application of mesenchymal stem cell in regenerative medicine: a narrative review. Stem Cell Res Ther. 2022;13(1):366.","journal-title":"Stem Cell Res Ther"},{"issue":"2","key":"3498_CR36","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1002\/stem.1867","volume":"33","author":"JJ Auletta","year":"2015","unstructured":"Auletta JJ, Eid SK, Wuttisarnwattana P, Silva I, Metheny L, Keller MD, et al. Human mesenchymal stromal cells attenuate graft-versus-host disease and maintain graft-versus-leukemia activity following experimental allogeneic bone marrow transplantation. Stem Cells. 2015;33(2):601\u201314.","journal-title":"Stem Cells"},{"issue":"1","key":"3498_CR37","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s13287-023-03380-x","volume":"14","author":"SCM Wu","year":"2023","unstructured":"Wu SCM, Zhu M, Chik SCC, Kwok M, Javed A, Law L, et al. Adipose tissue-derived human mesenchymal stromal cells can better suppress complement lysis, engraft and inhibit acute graft-versus-host disease in mice. Stem Cell Res Ther. 2023;14(1):167.","journal-title":"Stem Cell Res Ther"},{"issue":"3","key":"3498_CR38","first-page":"225","volume":"3","author":"IB Resnick","year":"2013","unstructured":"Resnick IB, Barkats C, Shapira MY, Stepensky P, Bloom AI, Shimoni A, et al. Treatment of severe steroid resistant acute GVHD with mesenchymal stromal cells (MSC). Am J Blood Res. 2013;3(3):225\u201338.","journal-title":"Am J Blood Res"},{"issue":"9624","key":"3498_CR39","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S0140-6736(08)60690-X","volume":"371","author":"K Le Blanc","year":"2008","unstructured":"Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet. 2008;371(9624):1579\u201386.","journal-title":"Lancet"},{"issue":"6","key":"3498_CR40","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1038\/bmt.2017.35","volume":"52","author":"GM Dotoli","year":"2017","unstructured":"Dotoli GM, De Santis GC, Orellana MD, de Lima PK, Caruso SR, Fernandes TR, et al. Mesenchymal stromal cell infusion to treat steroid-refractory acute GvHD III\/IV after hematopoietic stem cell transplantation. Bone Marrow Transpl. 2017;52(6):859\u201362.","journal-title":"Bone Marrow Transpl"},{"issue":"1","key":"3498_CR41","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13287-022-02751-0","volume":"13","author":"Y Li","year":"2022","unstructured":"Li Y, Hao J, Hu Z, Yang YG, Zhou Q, Sun L, et al. Current status of clinical trials assessing mesenchymal stem cell therapy for graft versus host disease: a systematic review. Stem Cell Res Ther. 2022;13(1):93.","journal-title":"Stem Cell Res Ther"},{"issue":"10","key":"3498_CR42","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/S0301-472X(03)00110-3","volume":"31","author":"K Le Blanc","year":"2003","unstructured":"Le Blanc K, Tammik C, Rosendahl K, Zetterberg E, Ringd\u00e9n O. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol. 2003;31(10):890\u20136.","journal-title":"Exp Hematol"},{"key":"3498_CR43","first-page":"69","volume":"449","author":"SG Dubois","year":"2008","unstructured":"Dubois SG, Floyd EZ, Zvonic S, Kilroy G, Wu X, Carling S, et al. Isolation of human adipose-derived stem cells from biopsies and liposuction specimens. Methods Mol Biol. 2008;449:69\u201379.","journal-title":"Methods Mol Biol"},{"issue":"2","key":"3498_CR44","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1111\/j.1582-4934.2007.00146.x","volume":"12","author":"LA Meza-Zepeda","year":"2008","unstructured":"Meza-Zepeda LA, Noer A, Dahl JA, Micci F, Myklebost O, Collas P. High-resolution analysis of genetic stability of human adipose tissue stem cells cultured to senescence. J Cell Mol Med. 2008;12(2):553\u201363.","journal-title":"J Cell Mol Med"},{"issue":"1","key":"3498_CR45","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13287-015-0066-5","volume":"6","author":"CY Li","year":"2015","unstructured":"Li CY, Wu XY, Tong JB, Yang XX, Zhao JL, Zheng QF, et al. Comparative analysis of human mesenchymal stem cells from bone marrow and adipose tissue under xeno-free conditions for cell therapy. Stem Cell Res Ther. 2015;6(1):55.","journal-title":"Stem Cell Res Ther"},{"issue":"11","key":"3498_CR46","doi-asserted-by":"publisher","first-page":"383","DOI":"10.3390\/jcm7110383","volume":"7","author":"K Kornicka","year":"2018","unstructured":"Kornicka K, \u015amieszek A, W\u0119grzyn AS, R\u00f6cken M, Marycz K. Immunomodulatory properties of adipose-derived stem cells treated with 5-azacytydine and resveratrol on peripheral blood mononuclear cells and macrophages in metabolic syndrome animals. J Clin Med. 2018;7(11):383.","journal-title":"J Clin Med"},{"issue":"1","key":"3498_CR47","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.healun.2014.09.029","volume":"34","author":"A Kapila","year":"2015","unstructured":"Kapila A, Baz MA, Valentine VG, Bhorade SM. Reliability of diagnostic criteria for bronchiolitis obliterans syndrome after lung transplantation: a survey. J Heart Lung Transpl. 2015;34(1):65\u201374.","journal-title":"J Heart Lung Transpl"},{"issue":"2","key":"3498_CR48","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ymeth.2008.03.006","volume":"45","author":"BA Bunnell","year":"2008","unstructured":"Bunnell BA, Flaat M, Gagliardi C, Patel B, Ripoll C. Adipose-derived stem cells: isolation, expansion and differentiation. Methods. 2008;45(2):115\u201320.","journal-title":"Methods"},{"issue":"6","key":"3498_CR49","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.bbmt.2015.02.025","volume":"21","author":"SJ Lee","year":"2015","unstructured":"Lee SJ, Wolff D, Kitko C, Koreth J, Inamoto Y, Jagasia M, et al. Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV: The 2014 Response Criteria Working Group report. Biol Blood Marrow Transpl. 2015;21(6):984\u201399.","journal-title":"Biol Blood Marrow Transpl"},{"key":"3498_CR50","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.ebiom.2019.09.039","volume":"49","author":"S Chen","year":"2019","unstructured":"Chen S, Zhao K, Lin R, Wang S, Fan Z, Huang F, et al. The efficacy of mesenchymal stem cells in bronchiolitis obliterans syndrome after allogeneic HSCT: a multicenter prospective cohort study. EBioMedicine. 2019;49:213\u201322.","journal-title":"EBioMedicine"},{"issue":"3","key":"3498_CR51","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1182\/blood-2007-02-074997","volume":"111","author":"GM Spaggiari","year":"2008","unstructured":"Spaggiari GM, Capobianco A, Abdelrazik H, Becchetti F, Mingari MC, Moretta L. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood. 2008;111(3):1327\u201333.","journal-title":"Blood"},{"issue":"5","key":"3498_CR52","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1016\/j.jtcvs.2013.09.041","volume":"147","author":"Y Zhao","year":"2014","unstructured":"Zhao Y, Gillen JR, Harris DA, Kron IL, Murphy MP, Lau CL. Treatment with placenta-derived mesenchymal stem cells mitigates development of bronchiolitis obliterans in a murine model. J Thorac Cardiovasc Surg. 2014;147(5):1668-77.e5.","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"4","key":"3498_CR53","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.intimp.2013.03.002","volume":"15","author":"Z Guo","year":"2013","unstructured":"Guo Z, Zhou X, Li J, Meng Q, Cao H, Kang L, et al. Mesenchymal stem cells reprogram host macrophages to attenuate obliterative bronchiolitis in murine orthotopic tracheal transplantation. Int Immunopharmacol. 2013;15(4):726\u201334.","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"3498_CR54","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.4049\/jimmunol.179.3.1855","volume":"179","author":"N Gupta","year":"2007","unstructured":"Gupta N, Su X, Popov B, Lee JW, Serikov V, Matthay MA. Intrapulmonary delivery of bone marrow-derived mesenchymal stem cells improves survival and attenuates endotoxin-induced acute lung injury in mice. J Immunol. 2007;179(3):1855\u201363.","journal-title":"J Immunol"},{"issue":"14","key":"3498_CR55","doi-asserted-by":"publisher","first-page":"8407","DOI":"10.1073\/pnas.1432929100","volume":"100","author":"LA Ortiz","year":"2003","unstructured":"Ortiz LA, Gambelli F, McBride C, Gaupp D, Baddoo M, Kaminski N, et al. Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci USA. 2003;100(14):8407\u201311.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"3498_CR56","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.trsl.2015.09.004","volume":"166","author":"J Tashiro","year":"2015","unstructured":"Tashiro J, Elliot SJ, Gerth DJ, Xia X, Pereira-Simon S, Choi R, et al. Therapeutic benefits of young, but not old, adipose-derived mesenchymal stem cells in a chronic mouse model of bleomycin-induced pulmonary fibrosis. Transl Res. 2015;166(6):554\u201367.","journal-title":"Transl Res"},{"key":"3498_CR57","doi-asserted-by":"publisher","first-page":"155066","DOI":"10.1016\/j.cyto.2020.155066","volume":"130","author":"P Mahdavi Sharif","year":"2020","unstructured":"Mahdavi Sharif P, Jabbari P, Razi S, Keshavarz-Fathi M, Rezaei N. Importance of TNF-alpha and its alterations in the development of cancers. Cytokine. 2020;130:155066.","journal-title":"Cytokine"},{"issue":"6","key":"3498_CR58","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1002\/stem.643","volume":"29","author":"JW Lee","year":"2011","unstructured":"Lee JW, Fang X, Krasnodembskaya A, Howard JP, Matthay MA. Concise review: mesenchymal stem cells for acute lung injury: role of paracrine soluble factors. Stem Cells. 2011;29(6):913\u20139.","journal-title":"Stem Cells"},{"issue":"4","key":"3498_CR59","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1002\/sctm.16-0372","volume":"6","author":"DC Chambers","year":"2017","unstructured":"Chambers DC, Enever D, Lawrence S, Sturm MJ, Herrmann R, Yerkovich S, et al. Mesenchymal stromal cell therapy for chronic lung allograft dysfunction: results of a first-in-man study. Stem Cells Transl Med. 2017;6(4):1152\u20137.","journal-title":"Stem Cells Transl Med"},{"issue":"2","key":"3498_CR60","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1002\/sctm.17-0198","volume":"7","author":"CA Keller","year":"2018","unstructured":"Keller CA, Gonwa TA, Hodge DO, Hei DJ, Centanni JM, Zubair AC. Feasibility, safety, and tolerance of mesenchymal stem cell therapy for obstructive chronic lung allograft dysfunction. Stem Cells Transl Med. 2018;7(2):161\u20137.","journal-title":"Stem Cells Transl Med"},{"issue":"9","key":"3498_CR61","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1093\/stcltm\/szac051","volume":"11","author":"DB Erasmus","year":"2022","unstructured":"Erasmus DB, Durand N, Alvarez FA, Narula T, Hodge DO, Zubair AC. Feasibility and safety of low-dose mesenchymal stem cell infusion in lung transplant recipients. Stem Cells Transl Med. 2022;11(9):891\u20139.","journal-title":"Stem Cells Transl Med"},{"issue":"3","key":"3498_CR62","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/bmt.2008.316","volume":"43","author":"M von Bonin","year":"2009","unstructured":"von Bonin M, St\u00f6lzel F, Goedecke A, Richter K, Wuschek N, H\u00f6lig K, et al. Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium. Bone Marrow Transpl. 2009;43(3):245\u201351.","journal-title":"Bone Marrow Transpl"},{"issue":"10","key":"3498_CR63","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1097\/01.tp.0000214462.63943.14","volume":"81","author":"O Ringd\u00e9n","year":"2006","unstructured":"Ringd\u00e9n O, Uzunel M, Rasmusson I, Remberger M, Sundberg B, L\u00f6nnies H, et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation. 2006;81(10):1390\u20137.","journal-title":"Transplantation"},{"issue":"12","key":"3498_CR64","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1038\/bmt.2010.195","volume":"45","author":"JY Weng","year":"2010","unstructured":"Weng JY, Du X, Geng SX, Peng YW, Wang Z, Lu ZS, et al. Mesenchymal stem cell as salvage treatment for refractory chronic GVHD. Bone Marrow Transpl. 2010;45(12):1732\u201340.","journal-title":"Bone Marrow Transpl"},{"issue":"8","key":"3498_CR65","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.jcyt.2017.05.002","volume":"19","author":"M Jurado","year":"2017","unstructured":"Jurado M, De La Mata C, Ruiz-Garc\u00eda A, L\u00f3pez-Fern\u00e1ndez E, Espinosa O, Remigia MJ, et al. Adipose tissue-derived mesenchymal stromal cells as part of therapy for chronic graft-versus-host disease: a phase I\/II study. Cytotherapy. 2017;19(8):927\u201336.","journal-title":"Cytotherapy"},{"issue":"10","key":"3498_CR66","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1002\/sctm.20-0099","volume":"9","author":"E Boberg","year":"2020","unstructured":"Boberg E, von Bahr L, Afram G, Lindstr\u00f6m C, Ljungman P, Heldring N, et al. Treatment of chronic GvHD with mesenchymal stromal cells induces durable responses: a phase II study. Stem Cells Transl Med. 2020;9(10):1190\u2013202.","journal-title":"Stem Cells Transl Med"},{"issue":"4","key":"3498_CR67","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1093\/stcltm\/szac003","volume":"11","author":"MDM Mac\u00edas-S\u00e1nchez","year":"2022","unstructured":"Mac\u00edas-S\u00e1nchez MDM, Morata-Tarifa C, Cuende N, Cardesa-Gil A, Cuesta-Casas M, Pascual-Cascon MJ, et al. Mesenchymal stromal cells for treating steroid-resistant acute and chronic graft versus host disease: a multicenter compassionate use experience. Stem Cells Transl Med. 2022;11(4):343\u201355.","journal-title":"Stem Cells Transl Med"},{"key":"3498_CR68","doi-asserted-by":"publisher","first-page":"959658","DOI":"10.3389\/fimmu.2022.959658","volume":"13","author":"E Stenger","year":"2022","unstructured":"Stenger E, Giver CR, Langston A, Kota D, Das PK, Chinnadurai R, et al. Safety of autologous freshly expanded mesenchymal stromal cells for the treatment of graft-versus-host disease. Front Immunol. 2022;13:959658.","journal-title":"Front Immunol"},{"key":"3498_CR69","doi-asserted-by":"publisher","first-page":"204062072110728","DOI":"10.1177\/20406207211072838","volume":"13","author":"MZ Shen","year":"2022","unstructured":"Shen MZ, Liu XX, Qiu ZY, Xu LP, Zhang XH, Wang Y, et al. Efficacy and safety of mesenchymal stem cells treatment for multidrug-resistant graft-versus-host disease after haploidentical allogeneic hematopoietic stem cell transplantation. Ther Adv Hematol. 2022;13:20406207211072840.","journal-title":"Ther Adv Hematol"},{"key":"3498_CR70","doi-asserted-by":"publisher","DOI":"10.1080\/02648725.2023.2183611","author":"Z Li","year":"2023","unstructured":"Li Z, Wang Y, Li G, Ma N, Li M, Yuan F, et al. Clinical observation on the safety and efficacy of umbilical cord mesenchymal stem cells in the treatment of bronchiolitis obliterans after allogeneic haematopoietic stem cell transplantation. Biotechnol Genet Eng Rev. 2023. https:\/\/doi.org\/10.1080\/02648725.2023.2183611.","journal-title":"Biotechnol Genet Eng Rev"},{"issue":"Suppl 5","key":"3498_CR71","first-page":"67","volume":"60","author":"H Kalhoff","year":"2009","unstructured":"Kalhoff H, Breidenbach R, Smith HJ, Marek W. Spirometry in preschool children: time has come for new reference values. J Physiol Pharmacol. 2009;60(Suppl 5):67\u201370.","journal-title":"J Physiol Pharmacol"},{"issue":"3","key":"3498_CR72","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1513\/AnnalsATS.202001-006OT","volume":"18","author":"RF Tamburro","year":"2021","unstructured":"Tamburro RF, Cooke KR, Davies SM, Goldfarb S, Hagood JS, Srinivasan A, et al. Pulmonary complications of pediatric hematopoietic cell transplantation: a national institutes of health workshop summary. Ann Am Thorac Soc. 2021;18(3):381\u201394.","journal-title":"Ann Am Thorac Soc"},{"issue":"8","key":"3498_CR73","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1183\/09031936.93.05080997","volume":"5","author":"PN Dekhuijzen","year":"1992","unstructured":"Dekhuijzen PN, Decramer M. Steroid-induced myopathy and its significance to respiratory disease: a known disease rediscovered. Eur Respir J. 1992;5(8):997\u20131003.","journal-title":"Eur Respir J"}],"container-title":["Stem Cell Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-023-03498-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13287-023-03498-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-023-03498-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T01:27:02Z","timestamp":1700357222000},"score":1,"resource":{"primary":{"URL":"https:\/\/stemcellres.biomedcentral.com\/articles\/10.1186\/s13287-023-03498-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,19]]},"references-count":73,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3498"],"URL":"https:\/\/doi.org\/10.1186\/s13287-023-03498-y","relation":{},"ISSN":["1757-6512"],"issn-type":[{"value":"1757-6512","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,19]]},"assertion":[{"value":"6 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study (<i>Evaluation of Safety and Effectiveness of Allogeneic Adipose-Derived Mesenchymal Stem Cells in Bronchiolitis Obliterans Syndrome (BoS) after Allogeneic Hematopoietic Stem Cell Transplantation<\/i>) is approved by the ethics committee of the Tehran University of Medical Sciences (IR.TUMS.MEDICINE.REC.1399.406) on 5 September 2020. All of our included cases\u2019 parents and donors of AT-MSCs were asked to complete and sign the written informed consent forms before participation in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The parents of included cases have consented to the anonymous publication of their children\u2019s data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"256"}}